Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izorlisib + Trastuzumab +/- Fulvestrant in Advanced HER2+ PIK3CA+ Breast Cancer
NCT03767335Phase 1Completed
- Sponsor
- Menarini Group
- Start
- Nov 2018
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of izorlisib in breast cancer, sponsored by Menarini Group. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicities at 28 days and 1 more. Started Nov 2018; status: completed.
02
Drugs
izorlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03767335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767335.